

Adjuvant Radiation Therapy for Ductal Carcinoma in Situ

Effective Date: May, 2015

Under Review

Background

Breast cancer is the most frequently diagnosed type of cancer for women in Alberta. There were 2,333 new cases of breast cancer in Alberta women and 385 deaths due to the disease in 2012, the most recent year for which these data are available.¹ Ductal carcinoma in situ (DCIS) of the breast is a heterogeneous group of proliferative cellular lesions that have the potential to become invasive.² DCIS is usually treated by surgically removing the cancer – mastectomy or breast-conserving surgery (BCS). After surgery, radiation therapy (RT) has commonly been recommended for many patients. The purpose of this guideline is to establish a standard of care for radiation, post-surgery for breast cancer patients with DCIS.

Guideline Questions

1. What is the optimal RT treatment after surgery (BCS or mastectomy) for patients with DCIS?
2. For patients with DCIS, how should a close radial margin of excision be handled following BCS?

Search Strategy

The original guideline was developed by searching MEDLINE (1966 through April 2008), EMBASE (1980 through April 2008), Cochrane Library, American Society of Clinical Oncology (ASCO) abstracts, and the CANCERLIT database. The search included practice guidelines, systematic reviews, meta-analyses, randomized controlled trials, and clinical trials. The search terms included breast, cancer* OR carcinoma OR tumour*, radiation OR radiotherapy, surgery OR conservation surgery, DCIS OR Ductal carcinoma in Situ.

Subsequent updates to the guideline are the result of deliberations of Alberta radiation oncologists at the 2012 and 2015 Annual Provincial Breast Tumour Team Meetings considering new evidence. A full systematic review of the literature and revamp of the guideline will be conducted in advance of the 2016 Annual Breast Tumour Team Meeting.

Target Population

These recommendations apply to adult patients with DCIS who have had BCS or a mastectomy.

Recommendations

For breast cancer patients with DCIS, recommendations are presented in Table 1 for the standard of care for adjuvant RT following surgery.

Table 1 Adjuvant RT for Patients with DCIS

Type of Surgery	
BCS	Mastectomy
<ul style="list-style-type: none"> • Adjuvant whole breast radiotherapy (WBRT) recommended • Partial breast RT investigational as part of clinical trial if available • For positive margins (ink on margin), re-excision recommended (close margin at fascia is an exception) • Pathologic/radiologic correlation required with margin width less than 2 mm; re-excision may be considered if there is discordance and based on individual case details • For close margins not treated with re-excision, the role of RT boost is not well defined 	<ul style="list-style-type: none"> • No adjuvant RT recommended, even if resection margins close. Adjuvant RT can be considered when margin positive but benefit not defined

Discussion

In 2014, a multidisciplinary panel of breast experts conducted a meta-analysis of margin width, and determined that a positive margin is a margin with ink on invasive carcinoma or DCIS, whereas a negative margin is a margin with no ink on the tumour, and that no further differentiation is required.³ If any controversy or uncertainty with regards to margins exists, the patient should be presented at rounds.

In the European Organization for Research and Treatment of Cancer (EORTC) 10853 trial, 1,010 women with DCIS measuring <5 cm were randomized to RT or no RT.⁴ At a median follow-up of 10.5 years, the 10-year local relapse-free rate was 74% for patients receiving no further treatment compared with 85% for patients receiving adjuvant RT (hazard ratio [HR], 0.53; 95% confidence interval [CI], 0.40-0.70, log rank. $p < 0.0065$). At a median follow-up of 10 years, the RT group, relative to the no-further-treatment group, had a reduced risk of invasive recurrence from 8% to 4% (HR=0.58; CI, 0.39-0.86).⁵ There were no significant differences in contralateral incidence, distant metastasis, death, or event-free survival.

In the National Surgical Adjuvant Breast Project (NSABP) protocol-B-17 trial, 818 DCIS patients with microscopically clear resection margins after BCS were randomized to RT, 5000 cGy in 25 fractions in five weeks, or observation.⁶⁻⁹ At a mean follow-up of 10.7 years, the 12-year cumulative incidence of invasive disease in the ipsilateral breast was reduced from 16.8% to 7.7% with RT ($p = 0.00001$). The rate of non-invasive recurrence was also reduced from 14.6% to 8.0% with RT ($p = 0.001$).

There was no significant difference in overall survival for patients treated with BCS alone versus BCS plus RT (86% vs. 87%; relative risk [RR], 0.95; 95% CI, 0.63-1.45; p=0.80). In a separate peer review paper, Fisher et al. reported lower recurrence rates for all nine pathologic characteristics in the radiation group compared to the observed group.^{7,10}

In the United Kingdom Coordinating Committee on Cancer Research (UKCCCR) trial, 1,030 patients were randomized after complete excision of DCIS to two (522 with RT and 502 without RT), and four arms (54% of the RT group received Tamoxifen and 51% in the non-RT group received Tamoxifen).¹¹ After a median follow-up of 52.6 months, there was a significant decrease in ipsilateral DCIS and invasive disease and no significant difference in contralateral DCIS or invasive disease.

Dose/Fractionation Schedule and Acute Toxicity

The three randomized trials in DCIS used the same dose, fractionation schedule, and 5000 cGy in 25 fractions in five weeks.^{5-9,11} Whereas the Ontario Clinical Oncology Group (OCOG) trial randomized 1,234 women with invasive disease treated with BCS to a course of 5000 cGy in 25 fractions over five weeks or a course of 4250 cGy in 16 fractions over three weeks.^{12,13} At a median follow-up of 69 months, the five-year local recurrence-free survival was 97.2% in the long arm (absolute difference, 0.4%; 95% CI = -1.5%- 2.4%). No difference was detected between arms in terms of disease-free or overall survival rates. The 16 fraction arm had better cosmetic outcome compared to the 25 fraction schedule (76.8% vs. 77.4%, absolute difference, 0.6%; 95% CI, -6.5%-5.5%). However, skin toxicity (Grade II or III) had a non-statistically significant higher incidence in the 16 fraction arm compared to the 25 fraction arm (absolute difference, 6%; 95% CI, -0.3%-10%), but there was no significant difference in the incidence of radiation pneumonitis. Only rib fracture in the 25 fraction arm was reported. This information suggests that the risk of toxicity from the 4250 cGy in 16 fractions protocol has a similar toxicity rate to the 5000cGy in 25 fractions protocol. There is no randomized data using the shorter fraction schedule in DCIS, but the OCOG data has been extrapolated to the DCIS population.

Side effects of radiotherapy

The side effects of modern breast RT are modest including altered pigmentation,¹⁴ breast discomfort, and firmness.^{15,16} The risk of cardiac disease is generally low with modern RT techniques.^{13,16,17} Several studies report an association between RT and cardiovascular morbidity, including myocardial infarction and congestive heart failure.^{18,19} In addition, a few studies have shown an increased risk of cardiovascular disease in patients who were treated with left-sided breast irradiation after breast-conserving therapy.^{20,21}

There is a higher risk of some malignancies in women receiving RT versus women not receiving RT. Increased RR was reported for lung cancer at 10-14 years and 15 or more years after initial breast cancer diagnosis (RR 1.62, 95% CI; 1.05-2.54 and RR 1.49, 95% CI; 1.05-2.14, respectively), for

second breast cancer at 5-10 years (RR 1.34; 95% CI, 1.10-1.63) and 15 + years (RR 1.26; 95% CI, 1.00-1.59) and oesophageal cancer at 15 or more years (RR 2.19; 95% CI, 1.10-4.62).²² However given the protracted interval between treatment and the development of another neoplasm in the irradiated field, many of these studies are old. The risk of a second malignancy related to breast cancer RT treatment is currently estimated to be approximately one per thousand women receiving RT.

References

1. CancerControl AB, Alberta Health Services. Surveillance & Reporting: 2012 Report on Cancer Statistics in Alberta. 2015.
2. Khurana A, McKean H, Kim H, Kim SH, mcguire J, Roberts LR, et al. Silencing of HSulf-2 expression in MCF10DCIS.com cells attenuate ductal carcinoma in situ progression to invasive ductal carcinoma in vivo. *Breast Cancer Res* 2012 Mar 12;14(2):R43 PubMed ID 22410125.
3. Moran MS, Schnitt SJ, Giuliano AE, Harris JR, Khan SA, Horton J, et al. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. *Int J Radiat Oncol Biol Phys* 2014 Mar 1;88(3):553-564 PubMed ID 24521674.
4. EORTC Breast Cancer Cooperative Group, EORTC Radiotherapy Group, Bijker N, Meijnen P, Peterse JL, Bogaerts J, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. *J Clin Oncol* 2006 Jul 20;24(21):3381-3387 PubMed ID 16801628.
5. Julien JP, Bijker N, Fentiman IS, Peterse JL, Delledonne V, Rouanet P, et al. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. *Lancet* 2000 Feb 12;355(9203):528-533 PubMed ID 10683002.
6. Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. *Semin Oncol* 2001 Aug;28(4):400-418 PubMed ID 11498833.
7. Fisher ER, Dignam J, Tan-Chiu E, Costantino J, Fisher B, Paik S, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma. *Cancer* 1999 Aug 1;86(3):429-438 PubMed ID 10430251.
8. Fisher B, Dignam J, Wolmark N, Mamounas E, Costantino J, Poller W, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B- 17. *J Clin Oncol* 1998 Feb;16(2):441-452 PubMed ID 9469327.
9. Fisher B, Costantino J, Redmond C, Fisher E, Margolese R, Dimitrov N, et al. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. *N Engl J Med* 1993 Jun 3;328(22):1581-1586 PubMed ID 8292119.
10. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. *CA Cancer J Clin* 2007 Jan-Feb;57(1):43-66 PubMed ID 17237035.
11. Houghton J, George WD, Cuzick J, Duggan C, Fentiman IS, Spittle M, et al. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. *Lancet* 2003 Jul 12;362(9378):95-102 PubMed ID 12867108.
12. National Cancer Institute. RAPID: Randomized Trial of Accelerated Partial Breast Irradiation. 2014; Available at: <http://clinicaltrials.gov/show/NCT00282035>, 2006.

13. Whelan T, MacKenzie R, Julian J, Levine M, Shelley W, Grimard L, et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. *J Natl Cancer Inst* 2002 Aug 7;94(15):1143-1150 PubMed ID 12165639.
14. Tho LM, McIntyre A, Rosst A, Gallagher C, Yap C, Ritchie DM, et al. Acute supraclavicular skin toxicity in patients undergoing radiotherapy for breast cancer: an evaluation of the 'T'-grip method of patient positioning. *Clin Oncol (R Coll Radiol)* 2006 Mar;18(2):133-138 PubMed ID 16523814.
15. Delaney G. Recent advances in the use of radiotherapy to treat early breast cancer. *Curr Opin Obstet Gynecol* 2005 Feb;17(1):27-33 PubMed ID 15711408.
16. Vinh-Hung V, Verschraegen C. Breast-conserving surgery with or without radiotherapy: pooled-analysis for risks of ipsilateral breast tumor recurrence and mortality. *J Natl Cancer Inst* 2004 Jan 21;96(2):115-121 PubMed ID 14734701.
17. Miller SR, Mondry T, Reed JS, Findley A, Johnstone PA. Delayed cellulitis associated with conservative therapy for breast cancer. *J Surg Oncol* 1998 Apr;67(4):242-245 PubMed ID 9579371.
18. Correa CR, Litt HI, Hwang WT, Ferrari VA, Solin LJ, Harris EE. Coronary artery findings after left-sided compared with right-sided radiation treatment for early-stage breast cancer. *J Clin Oncol* 2007 Jul 20;25(21):3031-3037 PubMed ID 17634481.
19. Hooning MJ, Botma A, Aleman BM, Baaijens MH, Bartelink H, Klijn JG, et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. *J Natl Cancer Inst* 2007 Mar 7;99(5):365-375 PubMed ID 17341728.
20. Harris EE, Correa C, Hwang WT, Liao J, Litt HI, Ferrari VA, et al. Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment. *J Clin Oncol* 2006 Sep 1;24(25):4100-4106 PubMed ID 16908933.
21. Borger JH, Hooning MJ, Boersma LJ, Snijders-Keilholz A, Aleman BM, Lintzen E, et al. Cardiotoxic effects of tangential breast irradiation in early breast cancer patients: the role of irradiated heart volume. *Int J Radiat Oncol Biol Phys* 2007 Nov 15;69(4):1131-1138 PubMed ID 17606332.
22. Roychoudhuri R, Evans H, Robinson D, Moller H. Radiation-induced malignancies following radiotherapy for breast cancer. *Br J Cancer* 2004 Aug 31;91(5):868-872 PubMed ID 15292931.

Development and Revision History

The recommendations contained in this guideline were developed by the Alberta Provincial Breast Tumour Team. Members of the Alberta Provincial Breast Tumour Team include medical, radiation and surgical oncologists, as well as nurses, pathologists and pharmacists. Evidence in support of the guidelines was selected and reviewed by a working group from the Tumour Team and a Knowledge Management Specialist from the Guideline Resource Unit. A detailed description of the methodology followed during guideline development can be found in the Guideline Resource Unit Handbook.

This guideline was originally developed in June 2008. This guideline was revised in April 2012, and June 2015.

Maintenance

A formal review of the guideline will be conducted in 2016. If critical new evidence is brought forward before that time, however, the guideline working group members will revise and update the document accordingly.

Abbreviations

ASCO, American Society of Clinical Oncology; BCS, Breast-conserving surgery; CI, Confidence interval; CRT, Conformal radiotherapy; DCIS, Ductal carcinoma in situ; EORTC, European Organization for Research and Treatment of Cancer; HR, Hazard ratio; MRM, Modified radical mastectomy; NSABP, National Surgical Adjuvant Breast Project; OCOG, Ontario Clinical Oncology Group; SLNB, Sentinel lymph node biopsy; UKCCCR, United Kingdom Coordinating Committee on Cancer Research; WBRT, Whole breast radiation therapy

Disclaimer

The recommendations contained in this guideline are a consensus of the Alberta Provincial Breast Tumour Team and are a synthesis of currently accepted approaches to management, derived from a review of relevant scientific literature. Clinicians applying these guidelines should, in consultation with the patient, use independent medical judgment in the context of individual clinical circumstances to direct care.

Copyright © (2015) Alberta Health Services

This copyright work is licensed under the [Creative Commons Attribution-NonCommercial-NoDerivative 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/). You are free to copy and distribute the work including in other media and formats for non-commercial purposes, as long as you attribute the work to Alberta Health Services, do not adapt the work, and abide by the other license terms. To view a copy of this license, see <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

The license does not apply to AHS trademarks, logos or content for which Alberta Health Services is not the copyright owner.

Funding Source

Financial support for the development of CancerControl Alberta's evidence-based clinical practice guidelines and supporting materials comes from the CancerControl Alberta operating budget; no outside commercial funding was received to support the development of this document.

All cancer drugs described in the guidelines are funded in accordance with the Outpatient Cancer Drug Benefit Program, at no charge, to eligible residents of Alberta, unless otherwise explicitly stated. For a complete list of funded drugs, specific indications, and approved prescribers, please refer to the [Outpatient Cancer Drug Benefit Program Master List](#).